Floxuridine - Article Fluorodeoxyuridine; FUDR
|Systematic (IUPAC) name|
|5-fluoro-1-[4-hydroxy-5- (hydroxymethyl)tetrahydrofuran-2-yl]- 1H-pyrimidine-2,4-dione|
|Mol. weight||246.193 g/mol|
|Pregnancy cat.|| |
Floxuridine, an analog of 5-Fluorouracil, is a fluorinated pyrimidine.
Meachanism of action
Floxuridine works because it is broken down by the body into its active form, which is the same as a metabolite of 5-Fluorouracil.
Floxuridine first gained FDA approval in December 1970 under the brand name FUDR. The drug was initially marketed by Roche, which also did a lot of the initial work on 5-flurouracil. The National Cancer Institute was an early developer of the drug. Roche sold its FUDR product line in 2001 to Faulding, which became Mayne Pharma.
In the US the drug is supplied by Mayne Pharma as well as APP and Bedford.
|Chemotherapeutic agents (L01) Chemotherapy regimens-|
|L01A - Alkylating agents: Cyclophosphamide | Chlorambucil | Melphalan | Mechlorethamine | Ifosfamide | Busulfan | ThioTEPA | Lomustine | Streptozocin | Temozolomide | Dacarbazine | Cisplatin | Carboplatin | Oxaliplatin | Procarbazine | Uramustine|
|L01B - Antimetabolites: Methotrexate | Pemetrexed | Fludarabine Cytarabine | Fluorouracil | Floxuridine | Gemcitabine | Capecitabine|
|L01C - Plant alkaloids: Vinblastine | Vincristine | Vinorelbine | Etoposide | Paclitaxel | Docetaxel|
|L01D - Cytotoxic/antitumour antibiotics: Anthracycline family (Doxorubicin | Daunorubicin | Epirubicin | Idarubicin | Mitoxantrone) | Bleomycin | Mitomycin | Hydroxyurea|
|L01X - Other, including Topoisomerase inhibitors: Topotecan | Irinotecan|